- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 562197, 9 pages
CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer
1Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
2Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
3Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
4Genomics Research Center, Academia Sinica, Taipei, Taiwan
5Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
6Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
7Department of Surgery, National Taiwan University Hospital, No. 7, Chung-Shan South Rd, Taipei 100, Taiwan
Received 2 July 2013; Revised 23 September 2013; Accepted 24 September 2013
Academic Editor: Franco M. Buonaguro
Copyright © 2013 Sung-Hsin Kuo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- EBCTCG, “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005.
- H. J. Burstein, A. A. Prestrud, J. Seidenfeld et al., “American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer,” Journal of Clinical Oncology, vol. 28, no. 23, pp. 3784–3796, 2010.
- Y. Zhao, C. R. Mendelson, E. R. Simpson, et al., “Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes,” Molecular Endocrinology, vol. 9, no. 3, pp. 340–349, 1995.
- S. E. Bulun, S. Sebastian, K. Takayama, T. Suzuki, H. Sasano, and M. Shozu, “The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters,” Journal of Steroid Biochemistry and Molecular Biology, vol. 86, no. 3–5, pp. 219–224, 2003.
- R. J. Santen, H. Brodie, E. R. Simpson, P. K. Siiteri, and A. Brodie, “History of aromatase: saga of an important biological mediator and therapeutic target,” Endocrine Reviews, vol. 30, no. 4, pp. 343–375, 2009.
- C. A. Haiman, S. E. Hankinson, D. Spiegelman, et al., “A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk,” International Journal of Cancer, vol. 87, no. 2, pp. 204–210, 2000.
- E. L. Goode, A. M. Dunning, B. Kuschel et al., “Effect of germ-line genetic variation on breast cancer survival in a population-based study,” Cancer Research, vol. 62, no. 11, pp. 3052–3057, 2002.
- C.-S. Huang, S.-H. Kuo, H.-C. Lien et al., “The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers,” Oncologist, vol. 13, no. 7, pp. 751–760, 2008.
- C. X. Ma, A. A. Adjei, O. E. Salavaggione et al., “Human aromatase: gene resequencing and functional genomics,” Cancer Research, vol. 65, no. 23, pp. 11071–11082, 2005.
- R. A. Paynter, S. E. Hankinson, G. A. Colditz, P. Kraft, D. J. Hunter, and I. De Vivo, “CYP19 (Aromatase) haplotypes and endometrial cancer risk,” International Journal of Cancer, vol. 116, no. 2, pp. 267–274, 2005.
- W. H. Xu, Q. Dai, Y. B. Xiang et al., “Interaction of soy food and tea consumption with CYP19 A1 genetic polymorphisms in the development of endometrial cancer,” American Journal of Epidemiology, vol. 166, no. 12, pp. 1420–1430, 2007.
- H. T. Meng, Q. Cai, Z.-F. Zhang et al., “Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 5, pp. 943–949, 2007.
- R. Colomer, M. Monzo, I. Tusquets et al., “A single-nucleotide polymorphismin the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma,” Clinical Cancer Research, vol. 14, no. 3, pp. 811–816, 2008.
- Z. Garcia-Casado, A. Guerrero-Zotano, A. Llombart-Cussac et al., “A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole,” BMC Cancer, vol. 10, article 36, 2010.
- A. G. Clark, “The role of haplotypes in candidate gene studies,” Genetic Epidemiology, vol. 27, no. 4, pp. 321–333, 2004.
- D. J. Schaid, “Evaluating associations of haplotypes with traits,” Genetic Epidemiology, vol. 27, no. 4, pp. 348–364, 2004.
- J. E. Olson, J. N. Ingle, C. X. Ma et al., “A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches,” Breast Cancer Research and Treatment, vol. 102, no. 2, pp. 237–247, 2007.
- S.-H. Kuo, H.-C. Lien, S.-L. You et al., “Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients,” Breast, vol. 17, no. 6, pp. 646–653, 2008.
- A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thürlimann, and H.-J. Senn, “Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009,” Annals of Oncology, vol. 20, no. 8, pp. 1319–1329, 2009.
- Y.-S. Lu, S.-H. Kuo, and C.-S. Huang, “Recent advances in the management of primary breast cancers,” Journal of the Formosan Medical Association, vol. 103, no. 8, pp. 579–598, 2004.
- M. Kaufmann, M. Morrow, G. Von Minckwitz, and J. R. Harris, “Locoregional treatment of primary breast cancer: consensus recommendations from an international expert panel,” Cancer, vol. 116, no. 5, pp. 1184–1191, 2010.
- S.-H. Tan, S.-C. Lee, B.-C. Goh, and J. Wong, “Pharmacogenetics in breast cancer therapy,” Clinical Cancer Research, vol. 14, no. 24, pp. 8027–8041, 2008.
- C. A. Hudis, W. E. Barlow, J. P. Costantino et al., “Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 2127–2132, 2007.
- C. A. Haiman, L. Dossus, V. W. Setiawan et al., “Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women,” Cancer Research, vol. 67, no. 5, pp. 1893–1897, 2007.
- S. E. Olivo-Marston, L. E. Mechanic, S. Mollerup et al., “Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women,” Carcinogenesis, vol. 31, no. 10, pp. 1778–1786, 2010.
- V. N. Kristensen, N. Harada, N. Yoshimura et al., “Genetic variants of CYP19 (aromatase) and breast cancer risk,” Oncogene, vol. 19, no. 10, pp. 1329–1333, 2000.
- L. Gennari, L. Masi, D. Merlotti et al., “A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2803–2810, 2004.
- P. C. de Jong, M. A. Blankenstein, J. van de Ven, J. W. R. Nortier, G. H. Blijham, and J. H. H. Thijssen, “Importance of local aromatase activity in hormone-dependent breast cancer: a review,” Breast, vol. 10, no. 2, pp. 91–99, 2001.
- Y. Miki, T. Suzuki, C. Tazawa et al., “Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells,” Cancer Research, vol. 67, no. 8, pp. 3945–3954, 2007.
- J.-R. Long, N. Kataoka, X.-O. Shu et al., “Genetic polymorphisms of the CYP19A1 gene and breast cancer survival,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 11, pp. 2115–2122, 2006.
- M. P. Goetz, J. M. Rae, V. J. Suman et al., “Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9312–9318, 2005.
- C. N. Falany, J. Wheeler, T. S. Oh, and J. L. Falany, “Steroid sulfation by expressed human cytosolic sulfotransferases,” Journal of Steroid Biochemistry and Molecular Biology, vol. 48, no. 4, pp. 369–375, 1994.
- C.-S. Huang, C.-H. Lin, Y.-S. Lu, and C.-Y. Shen, “Unique features of breast cancer in Asian women-Breast cancer in Taiwan as an example,” Journal of Steroid Biochemistry and Molecular Biology, vol. 118, no. 4-5, pp. 300–303, 2010.
- D. F. Easton, K. A. Pooley, A. M. Dunning, et al., “Genome-wide association study identifies novel breast cancer susceptibility loci,” Nature, vol. 447, no. 7148, pp. 1087–1093, 2007.
- S. H. Nordgard, F. E. Johansen, G. I. G. Alnæs, B. Naume, A.-L. Børresen-Dale, and V. N. Kristensen, “Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes,” Breast Cancer Research, vol. 9, no. 6, article 113, 2007.
- S. Bayraktar, P. A. Thompson, S. Y. Yoo, et al., “The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes,” The Oncologist, vol. 18, no. 5, pp. 493–500, 2013.
- S. Chen, J. Ye, I. Kijima, Y. Kinoshita, and D. Zhou, “Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue,” Journal of Steroid Biochemistry and Molecular Biology, vol. 95, no. 1–5, pp. 17–23, 2005.